Dialysis-related amyloidosis - UpToDate
uptodate.com · 404 words · saved by 1 readers
{{configCtrl2.info.metaDescription}}
Dialysis-related amyloidosis Authors:Jonathan Kay, MDWajeh Y Qunibi, MD Section Editors:Jeffrey S Berns, MDSteve J Schwab, MD, FACP, FASN Deputy Editor:Eric N Taylor, MD, MSc, FASN Literature review current through: Aug 2026. This topic last updated: Oct 07, 2025. INTRODUCTION Dialysis-related amyloidosis (DRA) is a disabling disease characterized by accumulation and tissue deposition of amyloid fibrils consisting of beta2-microglobulin (beta2-m) in the bone, periarticular structures, and viscera of patients with end-stage kidney disease [1-8]. Beta2-m is a component of the major…
related reading
- Diabetic Nephropathy - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
- Amyloidosis - Symptoms, Causes, Treatment | NORDrarediseases.org
- My Left Kidney - by Scott Alexander - Astral Codex Tenastralcodexten.com
- The amyloid hypothesis in Alzheimer disease: new insights from new therapeuticsnature.com
- Autosomal Dominant Polycystic Kidney Disease - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
- ALS - Wikipediaen.wikipedia.org
- The Glymphatic System – A Beginner's Guidencbi.nlm.nih.gov
- Dilated Cardiomyopathy - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
- Complications of the Type 2 Diabetes Mellitusncbi.nlm.nih.gov
- It’s just a first step, but this new Alzheimer’s drug could be a huge breakthrough | Jonathan Schott | The Guardiantheguardian.com
- The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes - PMCncbi.nlm.nih.gov
- APOE2 is associated with longevity independent of Alzheimer’s diseasencbi.nlm.nih.gov